Skip to main content
OSE Immunotherapeutics logo

OSE Immunotherapeutics — Investor Relations & Filings

Ticker · OSE ISIN · FR0012127173 LEI · 969500HIUWVGY6NZSM05 PA Manufacturing
Open in API
Filings indexed 815 across all filing types
Latest filing 2025-05-21 Regulatory Filings
Country FR France
Listing PA OSE

About OSE Immunotherapeutics

https://www.ose-immuno.com/en/home/

OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering first-in-class therapies that control the immune system. The company's pipeline is concentrated in two key areas: immuno-oncology (IO) and immuno-inflammation (I&I). In immuno-oncology, its research aims to help the immune system recognize and target tumors. In immuno-inflammation, it develops treatments for autoimmune diseases and chronic inflammation by regulating immune responses. OSE Immunotherapeutics utilizes proprietary drug discovery platforms to generate novel product candidates, including monoclonal antibodies and RNA therapeutics, and collaborates with pharmaceutical partners to advance its assets through clinical development.

Recent filings

Filing Released Lang Actions
OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies
Regulatory Filings Classification · 99% confidence The document is titled "OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies" and details a new partnership, funding secured (€1.3 million from Bpifrance), and the goals of the 'HexARN' program. It includes quotes from management and descriptions of the involved entities (Inside Therapeutics, MiNT Laboratory, OSE Immunotherapeutics). This content structure—announcing a significant business development, partnership, or funding event—is characteristic of a press release or a general corporate announcement. It is not a formal regulatory filing like a 10-K, an Earnings Release (ER), or a detailed Interim Report (IR). Since it announces a strategic business development and funding, it fits best under the general category for corporate news that isn't strictly financial reporting or management changes, making it a candidate for Regulatory Filings (RNS) as a general announcement, or potentially Capital/Financing Update (CAP) due to the funding mention. However, the primary focus is the strategic collaboration itself, which is a general corporate event announcement. Given the options, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for a press release detailing a strategic partnership and non-dilutive funding, as it doesn't fit the specific financial report codes (10-K, IR, ER) or management change codes (MANG).
2025-05-21 English
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations relatives au nombre total de droits de vote et d'actions composant le capital" (Information relating to the total number of voting rights and shares comprising the capital). It explicitly states that it is published in application of French commercial code (Article L. 233-8 II) and AMF general regulation (Article 223-16), and provides a breakdown of the total number of shares and voting rights as of April 30, 2025. This content directly relates to reporting changes in share capital structure and voting power, which aligns best with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), although it is a periodic update rather than a result of a specific vote. However, given the options, DVA is the closest fit for official capital/voting rights reporting outside of standard financial reports (10-K/IR). It is not a Director's Dealing (DIRS) as it reports total capital, not individual transactions. It is not a Share Issue (SHA) as it is a periodic disclosure of the current total, not an announcement of a new issue. Therefore, DVA is the most appropriate classification for this specific regulatory disclosure regarding voting rights and capital structure.
2025-05-06 French
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab
Regulatory Filings Classification · 99% confidence The document is titled with a headline announcing clinical trial results for a drug ('Lusvertikimab') and includes specific dates (May 5, 2025), company identification (OSE Immunotherapeutics SA), and quotes from management and investigators. It details Phase 2 study findings (CoTikiS) presented at a medical conference (DDW 2025). This structure—a formal announcement of scientific/clinical data, often referencing a presentation or publication—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical milestones. Since it focuses purely on clinical data updates and does not contain comprehensive financial statements (like a 10-K or IR) or explicitly state it is an 'Earnings Release,' the most fitting category for a major, time-sensitive operational update that is not a formal regulatory filing (like 10-K) or a transcript is the Earnings Release (ER) category, as these often include key operational highlights alongside any financial context, or, if purely clinical, it falls under a general announcement. Given the content is a press release announcing positive clinical data, ER is the closest fit among the options for a major periodic update, although it is not strictly financial earnings. However, if we strictly follow the definitions, it is a press release announcing scientific progress. Since there is no 'Press Release' category, and it is not a transcript (CT), a formal report (10-K, IR), or a management discussion (MDA), it functions as a major announcement. In many databases, significant clinical updates are grouped with ERs or RNS. Given the length and detail, it is more than just a 'Report Publication Announcement' (RPA). I will classify it as an Earnings Release (ER) as these often serve as the primary vehicle for communicating major operational/clinical progress to the market, even if financial figures are minimal or absent, or as RNS if it's purely regulatory news. Since this is a proactive announcement of positive data, ER is a strong candidate for a major market-moving announcement. If it were purely a notice that a report was available, it would be RPA. Since it contains the substance of the announcement, ER is chosen over RNS (the general fallback).
2025-05-05 English
OSE Immunotherapeutics annonce que plus de 90% des patients répondeurs ont maintenu une rémission symptomatique pendant la période d’extension sous Lusvertikimab
Earnings Release Classification · 90% confidence The document is a press release dated May 5, 2025, announcing positive clinical trial results (CoTikiS study extension data) for the drug Lusverkimab in treating Ulcerative Colitis (RCH). It details efficacy and safety data, quotes company executives and an investigator, and mentions the presentation of these results at the DDW 2025 conference. This content structure—a formal announcement of scientific/clinical progress, often released outside of standard quarterly reporting cycles—is characteristic of an Earnings Release (ER) if it were summarizing financial performance, or more generally, a press release announcing significant corporate/scientific news. Since it is focused purely on clinical trial data updates and not financial results (like revenue/net income), it is best classified as an announcement of important company information. Given the options, it most closely resembles an Earnings Release (ER) in format (a press release announcing key updates), but since the content is purely clinical/scientific progress, it is often categorized under general Regulatory Filings (RNS) if no specific category fits. However, in many financial databases, significant clinical trial updates that drive investor interest are often grouped with Earnings Releases (ER) or Investor Presentations (IP). Since it is a formal announcement of results, and not a presentation itself (IP) or a regulatory filing fallback (RNS), and it is not a full financial report (10-K/IR), the closest fit among the provided options that captures a time-sensitive, results-driven announcement is 'Earnings Release' (ER), as these often include operational/clinical highlights alongside financial figures, or 'Regulatory Filing' (RNS) as a general announcement. Given the focus on clinical data presentation at a conference, it is a key piece of investor information. Since it is a formal press release announcing results, and not a short notice about a report being available (RPA), I will classify it as an Earnings Release (ER) as it functions as a major operational update, or RNS as a general announcement. Given the context of a biotech company, major clinical data releases are often treated as equivalent to earnings announcements in terms of market impact. I will select ER as the primary type for a major results announcement, though RNS is a strong secondary candidate. Q2 2025
2025-05-05 French
Document d'Enregistrement Universel 2024
Annual Report Classification · 100% confidence The document is titled 'Document d'Enregistrement Universel 2024 incluant le Rapport Financier Annuel' and is filed with the AMF (Autorité des marchés financiers) under EU Regulation 2017/1129. It includes comprehensive sections such as risk factors, business overview, financial situation, capital structure, regulatory environment, and detailed financial statements. The length is substantial (15,000 characters and more), indicating it is a full report rather than a brief announcement. The document explicitly states it includes the annual financial report and audit reports. This matches the characteristics of an Annual Report (10-K equivalent) which covers full company activity and financial performance for the year. Therefore, the correct classification is Annual Report (10-K). FY 2024
2025-04-30 French
Mise à disposition du Document d’Enregistrement Universel incluant le Rapport Financier 2024
Report Publication Announcement Classification · 99% confidence The document is titled "Mise à disposition du Document d'Enregistrement Universel incluant le Rapport Financier 2024" (Making available the Universal Registration Document including the 2024 Financial Report). It explicitly states that the Universal Registration Document (which includes the annual financial report and corporate governance report) has been filed with the AMF (Autorité des Marchés Financiers) and provides links to access it. The document itself is short and serves primarily to announce the availability of the main regulatory filing, rather than being the full report (like a 10-K or IR). According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating a report has been published points towards a Report Publication Announcement (RPA). Although the content relates to an Annual Report (10-K equivalent in structure, as it contains the annual financial report), the document's function here is the announcement of its publication.
2025-04-30 French

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.